Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00771108 · ClinicalTrials.gov registry record · NA

Exercise Dose and Nonalcoholic Fatty Liver Disease

A NA study of Non-Alcoholic Fatty Liver Disease (NAFLD), sponsored by Washington University School of Medicine.

Completed
Registry status
NA
Development phase
33
Enrollment target
1
Study location

NCT00771108: Completed NA study of Non-Alcoholic Fatty Liver Disease (NAFLD), sponsored by Washington University School of Medicine.

NCT00771108 is a NA study of Non-Alcoholic Fatty Liver Disease (NAFLD) that has completed, run by Washington University School of Medicine. The registered enrollment target is 33 participants, below the 88-participant average among 9 other Non-Alcoholic Fatty Liver Disease (NAFLD) trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00771108, a NA study of Non-Alcoholic Fatty Liver Disease (NAFLD), has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to provide a better understanding of how exercise (walking) affects non-alcoholic fatty liver disease (NAFLD) in overweight people. NAFLD, which is common in obese people, occurs when the liver has too much fat.

Interventions

  • BEHAVIORAL exercise

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2006-05
Est. Completion 2011-04
Phase NA

What the finished NCT00771108 record still lists

NCT00771108 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 88-participant average among 9 other Non-Alcoholic Fatty Liver Disease (NAFLD) trials with a reported enrollment target (62% lower).

The record links to 1 condition, with Non-Alcoholic Fatty Liver Disease (NAFLD) appearing as the primary indexed condition, and to 1 intervention - of which exercise is the first listed.

NCT00771108 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT00771108 about?

NCT00771108 is a clinical study titled "Exercise Dose and Nonalcoholic Fatty Liver Disease". The purpose of this research is to provide a better understanding of how exercise (walking) affects non-alcoholic fatty liver disease (NAFLD) in overweight people. NAFLD, which is common in obese people, occurs when the liver has too much fat.

What is the current status of trial NCT00771108?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2006-05. Estimated completion is 2011-04.

What conditions does trial NCT00771108 study?

This clinical trial studies the following conditions: Non-Alcoholic Fatty Liver Disease (NAFLD).

What interventions are being tested in trial NCT00771108?

The interventions under investigation include: exercise (BEHAVIORAL).

Who is sponsoring clinical trial NCT00771108?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00771108 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Alcoholic Fatty Liver Disease (NAFLD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00771108's enrollment target sits among peer trials

33 7th of 9 higher than 3 of 9 other Non-Alcoholic Fatty Liver Disease (NAFLD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Alcoholic Fatty Liver Disease (NAFLD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00771108, the US trial registry maintained by the National Library of Medicine. NCT00771108 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.